Disclosed are ribozymes, as well as compositions, vectors, virus
particles, host cells, and therapeutic kits comprising them useful in the
treatment of diseases of the eye, including retinopathy and macular
degeneration, and the amelioration of symptoms of such diseases including
loss of vision, retinitis, and blindness.
